Weight Loss Including GLP-1 Drugs Improves Insulin Resistance and Menstrual Cycles in PCOS

Weight loss interventions significantly improved HOMA-IR (-0.45, CI -0.75 to -0.15), free androgen index (-2.03, CI -3.0 to -1.07), and menstrual frequency (+2.64, CI 0.65-4.63). Nine trials used GLP-1 agonists. No significant effect on hirsutism or quality of life. Published in Annals of Internal Medicine.

Systematic review and meta-analysis. Searched MEDLINE, Embase, PsycINFO, CINAHL, Cochrane, and Web of Science through June 2024. Included RCTs comparing weight loss interventions to usual care in PCOS. 29 comparisons, 1,529 participants. Random-effects meta-analysis with Knapp-Hartung adjustment. Risk of bias assessed for each study.

PCOS affects 8-13% of women of reproductive age and is closely linked to obesity. While guidelines recommend weight loss, this is the most comprehensive evidence to date showing which PCOS features actually improve — and which don't — validating weight loss as a core PCOS treatment strategy.

With GLP-1 peptide drugs producing unprecedented weight loss, this meta-analysis provides the evidence base for deploying these medications specifically for PCOS. The finding that weight loss restores menstrual cycles and reduces androgens could reshape PCOS management toward metabolic-first approaches.

High statistical heterogeneity across interventions and comparators. Most studies had high or some risk of bias. GLP-1 trials not analyzed separately in the primary analysis. No evidence of hirsutism or QoL improvement, though may be due to limited power. Short study durations may miss long-term benefits.